a day ago
Stifel Nicolaus Remains a Buy on RegenXBio (RGNX)
In a report released today, Annabel Samimy from Stifel Nicolaus reiterated a Buy rating on RegenXBio (RGNX – Research Report), with a price target of $40.00. The company's shares opened today at $9.72.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Samimy is a 4-star analyst with an average return of 4.0% and a 42.89% success rate. Samimy covers the Healthcare sector, focusing on stocks such as Trevi Therapeutics, RegenXBio, and Altimmune.
Currently, the analyst consensus on RegenXBio is a Strong Buy with an average price target of $31.27, representing a 221.71% upside. In a report released on May 28, Leerink Partners also maintained a Buy rating on the stock with a $19.00 price target.
